← All trials
NCT05583110
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2023
- Primary completion
- Aug 31, 2026
- Completion date
- Aug 31, 2026
- First posted
- Oct 17, 2022
- Last posted
- Oct 19, 2022
- Enrollment
- 49
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Spanish Breast Cancer Research GroupLead sponsor
- Universidad de CordobaStudy director
- Seattle GeneticsCollaborator
- Hospital General Universitario Gregorio MarañonOfficial
- Universidad de CordobaOfficial
- OsakidetzaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.